Cellectar Biosciences, Inc. (CLRB) Stock Price & Analysis
Cellectar Biosciences, Inc. (CLRB) fell 2.43% to USD 2.41 as of July 25, 2026 at 06:10 UTC, according to Nexqual real-time market data.
CLRB last closed at USD 2.47; the session ranged USD 2.36–2.55 on volume of 35,969 shares. Market capitalization is $19.26M, with a 52-week range of USD 2.2–6.52 (NCM). Source: Nexqual, July 25, 2026 at 06:10 UTC.
Key Statistics (as of July 25, 2026 at 06:10 UTC)
| Price | USD 2.41 |
|---|---|
| Change | ▼ 2.43% (down) |
| Previous Close | USD 2.47 |
| Open | USD 2.45 |
| Day Range | USD 2.36 – 2.55 |
| 52-Week Range | USD 2.2 – 6.52 |
| Volume | 35,969 shares |
| Market Cap | $19.26M |
| Exchange | NCM |
Technical Analysis (CLRB)
Nexqual's technical model rates CLRB "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:10 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.99 (neutral) |
| vs SMA50 | Below (USD 2.71) |
| MACD | -0.06 (negative) |
Analyst Ratings (CLRB)
Wall Street analysts rate CLRB "Strong Buy" based on 4 analysts, with a mean price target of USD 11.5 (range USD 10–15), per Nexqual as of July 25, 2026 at 06:10 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 11.5 |
| High Target | USD 15 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (CLRB)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.52 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.33 vs est -1.89 ▲ beat |
| 2025-12-31 | USD -0.53 vs est -1.23 ▲ beat |
| 2025-09-30 | USD -1.41 vs est -2.53 ▲ beat |
| 2025-06-30 | USD -3.39 vs est -3.7 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Financials & Fundamentals (CLRB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -290.42% |
| Debt / Equity | 32.41 |
| Current Ratio | 1.9 |
| Total Cash | $8.35M |
| Total Debt | $1.53M |
| Free Cash Flow | $-12.78M |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Financial Health Score (CLRB)
Nexqual rates Cellectar Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $8M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$19M |
| Efficiency | Critical — ROE -290%, ROA -103.0% |
Ownership (CLRB)
| Insider Ownership | +2.07% |
|---|---|
| Institutional Ownership | +16.66% |
| Shares Outstanding | 7.99M |
| Float | 7.82M |
| Short % of Float | +2.51% |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Leadership (CLRB)
Cellectar Biosciences, Inc. is led by James V. Caruso (age 66), President, CEO & Director, per Nexqual as of July 25, 2026 at 06:10 UTC.
| President, CEO & Director | James V. Caruso (age 66) |
|---|---|
| VP, CFO & Secretary | Chad J. Kolean (age 61) |
| Chief Operating Officer | Jarrod Longcor (age 52) |
Major Backers & Investors (CLRB)
Notable institutional backers of Cellectar Biosciences, Inc. include Bleichroeder LP, Fidelity, Sequoia Financial Advisors, LLC, according to Nexqual as of July 25, 2026 at 06:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bleichroeder LP | 1.25% |
| Fidelity | 0.44% |
| Sequoia Financial Advisors, LLC | 0.27% |
| Warberg Asset Management LLC | 0.17% |
| Riverview Capital Advisers, LLC | 0.13% |
| UBS Group AG | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.26% |
| Geode Capital | 0.66% |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
From Cellectar Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
- It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program.
- The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PULM | Pulmatrix, Inc. | USD 1.65 | ▼ 2.37% |
| MBRX | Moleculin Biotech, Inc. | USD 2.12 | ▲ 0.95% |
| HEPA | Hepion Pharmaceuticals, Inc. | USD 0.05 | ▲ 1.89% |
| BLRX | BioLineRx Ltd. | USD 2.82 | ▼ 1.05% |
| CBIO | Crescent Biopharma, Inc. | USD 16.3 | ▲ 2.97% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:10 UTC. This page is informational and not investment advice.